Wen Xu1, Di Liu2, Yang Yang3, Xi Ding4, Yifeng Sun3, Baohong Zhang5, Jinfu Xu1, Bo Su4. 1. Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China. 2. Department of Oncology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China. 3. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China. 4. Central Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China. 5. School of Pharmacy, Shanghai Jiaotong University, Shanghai 200240, China.
Abstract
BACKGROUND: Cell cycle checkpoint kinase 2 (CHEK2) plays an essential role in the repair of DNA damage. Single nucleotide polymorphisms (SNPs) in DNA repair genes are thought to influence treatment effects and survival of cancer patients. This study aimed to investigate the relationship between polymorphisms in the CHEK2 gene and efficacy of platinum-based doublet chemotherapy in never-smoking Chinese female patients with advanced non-small-cell lung cancer (NSCLC). METHODS: Using DNA from blood samples of 272 Chinese advanced NSCLC non-smoking female patients treated with first-line platinum-based chemotherapy, we have analyzed the relationships between four SNPs in the CHEK2 gene and clinical outcomes. RESULTS: We found that overall survival (OS) was significantly associated with CHEK2 rs4035540 (Log-Rank P=0.020), as well as the CHEK2 rs4035540 dominant model (Log-Rank P=0.026), especially in the lung adenocarcinoma group. After multivariate analysis, patients with rs4035540 A/G genotype had a significantly better OS than those with the G/G genotype (HR =0.67, 95% CI, 0.48-0.93; P=0.016). In the toxicity analysis, it was observed that patients with the CHEK2 rs4035540 A/A genotype had a higher risk of gastrointestinal toxicity than the G/G genotype group (P=0.009). However, there are no significant associations between chemotherapy treatments and genetic variations. CONCLUSIONS: Our findings indicate that SNPs in CHEK2 are related to Chinese advanced NSCLC never-smoking female patients receiving platinum-based doublet chemotherapy in China. Patients with rs4035540 A/G genotype have a better OS. And patients with rs4035540 A/A genotype have a higher risk of gastrointestinal toxicity. These results point to a direction for predicting the prognosis for Chinese never-smoking NSCLC female patients. However, there are no significant associations between chemotherapy treatments and SNPs in CHEK2, which need more samples to the further study.
BACKGROUND: Cell cycle checkpoint kinase 2 (CHEK2) plays an essential role in the repair of DNA damage. Single nucleotide polymorphisms (SNPs) in DNA repair genes are thought to influence treatment effects and survival of cancerpatients. This study aimed to investigate the relationship between polymorphisms in the CHEK2 gene and efficacy of platinum-based doublet chemotherapy in never-smoking Chinese female patients with advanced non-small-cell lung cancer (NSCLC). METHODS: Using DNA from blood samples of 272 Chinese advanced NSCLC non-smoking female patients treated with first-line platinum-based chemotherapy, we have analyzed the relationships between four SNPs in the CHEK2 gene and clinical outcomes. RESULTS: We found that overall survival (OS) was significantly associated with CHEK2rs4035540 (Log-Rank P=0.020), as well as the CHEK2rs4035540 dominant model (Log-Rank P=0.026), especially in the lung adenocarcinoma group. After multivariate analysis, patients with rs4035540 A/G genotype had a significantly better OS than those with the G/G genotype (HR =0.67, 95% CI, 0.48-0.93; P=0.016). In the toxicity analysis, it was observed that patients with the CHEK2rs4035540 A/A genotype had a higher risk of gastrointestinal toxicity than the G/G genotype group (P=0.009). However, there are no significant associations between chemotherapy treatments and genetic variations. CONCLUSIONS: Our findings indicate that SNPs in CHEK2 are related to Chinese advanced NSCLC never-smoking female patients receiving platinum-based doublet chemotherapy in China. Patients with rs4035540 A/G genotype have a better OS. And patients with rs4035540 A/A genotype have a higher risk of gastrointestinal toxicity. These results point to a direction for predicting the prognosis for Chinese never-smoking NSCLC female patients. However, there are no significant associations between chemotherapy treatments and SNPs in CHEK2, which need more samples to the further study.
Entities:
Keywords:
Cell cycle checkpoint kinase 2 (CHEK2); chemotherapy; never-smoking women; non-small-cell lung cancer (NSCLC); single nucleotide polymorphisms (SNPs)
Authors: Li Zheng; Fengwei Wang; Chiping Qian; Roxann M Neumann; John C Cheville; Donald J Tindall; Wanguo Liu Journal: Hum Mutat Date: 2006-10 Impact factor: 4.878
Authors: X Zhu; L Shan; F Wang; J Wang; F Wang; G Shen; X Liu; B Wang; Y Yuan; J Ying; H Yang Journal: Breast Cancer Res Treat Date: 2015-03-18 Impact factor: 4.872
Authors: Tracy A O'Mara; Kaltin Ferguson; Paul Fahey; Louise Marquart; Hannah P Yang; Jolanta Lissowska; Stephen Chanock; Montserrat Garcia-Closas; Deborah J Thompson; Catherine S Healey; Alison M Dunning; Douglas F Easton; Penelope M Webb; Amanda B Spurdle Journal: Twin Res Hum Genet Date: 2011-08 Impact factor: 1.587